Peter Attia MD204 - Centenarians, metformin, and longevity | Nir Barzilai, M.D.
At a glance
WHAT IT’S REALLY ABOUT
Nir Barzilai on Centenarian Genetics, Metformin, TAME Trial, and Longevity
- Barzilai explains that centenarians do not have perfect genomes or healthy habits; instead they carry longevity genotypes, most notably variants that dampen growth hormone/IGF-1 signaling, found in about 60% of his centenarians.
- The two discuss specific longevity-linked genes and traits, including CETP, APOC3, APOE e2, Klotho, FOXO3A and high TSH, and how the genetics of longevity in humans converge on the insulin/IGF, mTOR and MAP kinase pathways seen in animals.
- Centenarians delay disease by 20 to 30 years and compress morbidity, but Attia pushes back that this may partly reflect frailty at the end, and both agree the practical lesson for most people is still exercise, nutrition and primary prevention.
- The TAME trial is designed to test metformin in people aged 65 to 79 without diabetes using a cluster of outcomes, with the aim of securing an FDA indication for targeting aging rather than a single disease.
- They debate metformin's evidence base and its possible blunting of fitness gains, discuss biomarkers of aging (proteomics over epigenetic clocks), and Barzilai expresses skepticism about NAD precursors.
IDEAS WORTH REMEMBERING
5 ideasCentenarians are not defined by perfect genes or perfect habits.
Barzilai says the first 44 sequenced centenarians each carried five to six variants linked to disease, and many centenarians smoke, are overweight and don't exercise, so protective longevity genes must be at work.
Reduced growth hormone/IGF-1 signaling is the most common longevity genotype in his cohort.
About 60% of his centenarians have genes impairing this pathway, including FOXO3A, and among centenarian women lower IGF-1 predicted living twice as long.
What helps when young can hurt when old.
In UK Biobank data, high IGF-1 was protective in young people but associated with more age-related disease and mortality over age 60, illustrating antagonistic pleiotropy.
Centenarians mostly delay disease rather than escape it.
Attia notes they die of similar causes as others, just decades later, while Barzilai adds they spend months rather than years sick and have lower end-of-life costs.
TAME aims to establish aging as a drug-approval target, not prove metformin works for everyone.
Its primary outcome is a cluster of mortality, cardiovascular events, cancer and MCI/dementia in 65 to 79 year olds without diabetes, and Barzilai says all he wants is an FDA indication for aging.
WORDS WORTH SAVING
5 quotesLet's say it's 20%, okay? Let's say it's 20%. If we understand this 20%, understand it really, we can use that in order to prevent the 80% of the environment.
— Nir Barzilai
The things that are good for you when you're young can turn against you when you're old.
— Nir Barzilai
I've never seen a worse biomarker than a biological clock. These are so easy to manipulate and game.
— Peter Attia
They have such a compression of morbidity, they are sick for months at the end of their life, unlike us that are sick for years at the end of our lives.
— Nir Barzilai
Secondary prevention is not prevention.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
